LitAlert ~~ GeneLit.com

    • Front-line ovarian cancer maintenance therapy: PARP inhibitors for all?
    • Berger J.
    • BJOG. 2020 Aug 8. doi: 10.1111/1471-0528.16450. Epub ahead of print.
    • Pinning Pink: Messages About Hereditary Breast Cancer Risk on Pinterest.
    • Miller CA, Henderson AN, Guidry JPD, McGuire KP, Fuemmeler BF.
    • J Cancer Educ. 2020 Aug 8. doi: 10.1007/s13187-020-01842-x. Epub ahead of print.
    • Exon splicing analysis of intronic variants in multi-gene cancer panel testing for hereditary breast/ovarian cancer.
    • Ryu JS, Lee HY, Cho EH, Yoon KA, Kim MK, Joo J, Lee ES, Kang HS, Lee S, Lee DO, Lim MC, Kong SY.
    • Cancer Sci. 2020 Aug 6. doi: 10.1111/cas.14600. Epub ahead of print.
    • The emerging role of PARP inhibitors in prostate cancer.
    • Stellato M, Guadalupi V, Sepe P, Mennitto A, Claps M, Zattarin E, Verzoni E, Valdagni R, De Braud FG, Santini D, Tonini G, Procopio G.
    • Expert Rev Anticancer Ther. 2020 Aug 6:1-12. doi: 10.1080/14737140.2020.1797497. Epub ahead of print.
    • Review
    • The identification of six risk genes for ovarian cancer platinum response based on global network algorithm and verification analysis.
    • Xing L, Mi W, Zhang Y, Tian S, Zhang Y, Qi R, Lou G, Zhang C.
    • J Cell Mol Med. 2020 Aug 6. doi: 10.1111/jcmm.15567. Epub ahead of print.
    • Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
    • Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, Alexandre J, You B, Bastian S, Krebs MG, Wang D, Waqar SN, Lanasa M, Rhee J, Gao H, Rocher-Ros V, Jones EV, Gulati S, Coenen-Stass A, Kozarewa I, Lai Z, Angell HK, Opincar L, Herbolsheimer P, Kaufman B.
    • Lancet Oncol. 2020 Aug 6:S1470-2045(20)30324-7. doi: 10.1016/S1470-2045(20)30324-7. Epub ahead of print.
    • Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis.
    • Borella F, Bertero L, Morrone A, Gambella A, Bovetti M, Cosma S, Carosso A, Katsaros D, Gemmiti S, Preti M, Valabrega G, Scotto G, Cassoni P, Benedetto C.
    • Cancers (Basel). 2020 Aug 4;12(8):E2156. doi: 10.3390/cancers12082156.
    • Hereditary diffuse gastric cancer: updated clinical practice guidelines.
    • Blair VR, McLeod M, Carneiro F, Coit DG, D'Addario JL, van Dieren JM, Harris KL, Hoogerbrugge N, Oliveira C, van der Post RS, Arnold J, Benusiglio PR, Bisseling TM, Boussioutas A, Cats A, Charlton A, Schreiber KEC, Davis JL, Pietro MD, Fitzgerald RC, Ford JM, Gamet K, Gullo I, Hardwick RH, Huntsman DG, Kaurah P, Kupfer SS, Latchford A, Mansfield PF, Nakajima T, Parry S, Rossaak J, Sugimura H, Svrcek M, Tischkowitz M, Ushijima T, Yamada H, Yang HK, Claydon A, Figueiredo J, Paringatai K, Seruca R, Bougen-Zhukov N, Brew T, Busija S, Carneiro P, DeGregorio L, Fisher H, Gardner E, Godwin TD, Holm KN, Humar B, Lintott CJ, Monroe EC, Muller MD, Norero E, Nouri Y, Paredes J, Sanches JM, Schulpen E, Ribeiro AS, Sporle A, Whitworth J, Zhang L, Reeve AE, Guilford P.
    • Lancet Oncol. 2020 Aug;21(8):e386-e397. doi: 10.1016/S1470-2045(20)30219-9.
    • Guidelines
    • Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer.
    • Boyarskikh UA, Gulyaeva LF, Avdalyan AM, Kechin AA, Khrapov EA, Lazareva DG, Kushlinskii NE, Melkonyan A, Arakelyan A, Filipenko ML.
    • Front Oncol. 2020 Jul 16;10:1103. doi: 10.3389/fonc.2020.01103.